Thiopurine methyltransferase in acute lymphoblastic leukemia.

We recently reported that specific genetic polymorphisms, particularly polymorphisms in thymidylate synthase (TYMS) and glutathione S -transferase M1 (GSTM1) predicted the risk of relapse among children with acute lymphoblastic leukemia (ALL).[1][1] An accompanying commentary noted surprise that the

[1]  M. Zwaan.  Toward individualized dosing in pediatric ALL , 2005 .

[2]  M. Schrappe,et al.  Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. , 2005, JAMA.

[3]  E. Cook,et al.  Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. , 2004, Blood.

[4]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[5]  M. Relling,et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[7]  M. Relling,et al.  High incidence of secondary brain tumours after radiotherapy and antimetabolites , 1999, The Lancet.

[8]  M. Relling,et al.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999, Blood.

[9]  F. Behm,et al.  Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia , 1998, Leukemia.

[10]  Ching-Hon Pui,et al.  Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.